The co-founder of bankrupt genetic analysis company 23andMe won an auction for the firm’s assets, agreeing, along with a ...

Zacks.com users have been paying close attention to JPMorgan Chase & Co. (JPM). This makes it worthwhile to examine what the stock has in store.

But what about the other end of the spectrum? Let's take a quick look at the two worst performers on the Nasdaq-100 in May 2025.

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

TB Alternative Assets Ltd. has joined the biotech investing party by purchasing 3,158 shares of Regeneron Pharmaceuticals ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

Through Friday, Capital One’s COF stock had returned 10.9% for 2025, while Discover shares had returned 16% as investors became more confident the deal would be completed. The KBW Bank Index had ...

IQVIA stock may look ready for a breakout, but Adhishthana analysis reveals a complex time spiral that could last until 2030.

A significant trading signal occurred for Regeneron Pharma stock at a price of $501.83, after which REGN rose up to 3.2%.

Chicago, IL – June 10, 2025 – Today, Zacks Equity Research discusses Sandoz SDZNY, Teva Pharmaceuticals TEVA and Viatris VTRS ...